http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002091248-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4716 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2001-05-08^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_250a658d049d67d913147f65ab4286dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f6bc280e0486060009795e66c42c447 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e386fed43c8bf4231ab8f64c36535540 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f51fef9b173077ad6bbec27769d09f40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_327084e173a4b7065efbc96752b66b0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc0f25b93d40e0cdc95b0677cf55bb6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8e013d7dc1be9583a8d7bc26b1b7639 |
| publicationDate | 2002-07-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002091248-A1 |
| titleOfInvention | Myosin IXa and cyclic nucleotide gated channel-15 (CNGC-15) polynucleotides, polypeptides, compositions, methods, and uses thereof |
| abstract | The present invention discloses the amino acid and nucleic acid sequences of a new CNGC and Myosin that map to the region of the human chromosome associated with Bardet-Biedl Syndrome. Cyclic nucleotide gated channels (CNGCs) comprise a family of multimeric protein ion channels that open in response to the binding of a cyclic nucleotide to an intracellular domain. The two new proteins, CNGC-15 and Myosin IXa, are useful in the study, diagnosis and treatment of Bardet-Biedl Syndrome and Usher Syndrome. Other indications that can be treated by CNGC-15 and/or Myosin IXa polypeptides, or agonists or antagonists include hearing loss, retinis pigmentosa, obesity, hypogonadism, sterility, polydactyly, brachydactyly, syndactyly, mental retardation, renal abnormalities, hypertension, diabetes and cardiovascular abnormalities. n Compositions and methods for expressing cyclic nucleotide gated channel-15 (CNGC-15) and Myosin IXa are provided. The compositions comprise CNGC-15 and Myosin IXa polypeptides and derivatives thereof, nucleotide sequences, expression cassettes, transformed cells and antibodies to these polypeptides. Methods for the expression and detection of CNGC-15 and Myosin IXa nucleotides and polypeptides and compositions for the treatment of these conditions are provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014164472-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9696323-B2 |
| priorityDate | 1997-10-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1933.
| Next Page | Last Page |